Key Points
- CEO Xingjuan Chao sold 50,000 shares on Nov. 21 at an average of $15.13 for $756,500, trimming her stake by 5.9% to 798,135 shares (about $12.08M).
- CeriBell beat Q3 estimates with EPS of -$0.37 (vs. -$0.43) and revenue of $22.59M, but remains unprofitable with negative ROE and net margin; the stock has a $643.7M market cap, a 52-week range of $10.01–$32.75, and a consensus analyst target of $25.17 (Moderate Buy).
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 50,000 shares of the stock in a transaction on Friday, November 21st. The stock was sold at an average price of $15.13, for a total transaction of $756,500.00. Following the transaction, the chief executive officer directly owned 798,135 shares in the company, valued at $12,075,782.55. The trade was a 5.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
CeriBell Price Performance
Shares of NASDAQ:CBLL opened at $17.35 on Wednesday. The stock has a market capitalization of $643.69 million and a P/E ratio of -11.49. The business has a 50-day moving average of $12.54 and a two-hundred day moving average of $14.35. CeriBell, Inc. has a fifty-two week low of $10.01 and a fifty-two week high of $32.75. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25.
CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The business had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. CeriBell has set its FY 2025 guidance at EPS. On average, equities research analysts predict that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts have weighed in on CBLL shares. Weiss Ratings reissued a "sell (e+)" rating on shares of CeriBell in a research report on Wednesday, October 8th. TD Cowen cut their target price on shares of CeriBell from $36.00 to $20.00 and set a "buy" rating for the company in a research note on Wednesday, November 5th. Raymond James Financial began coverage on shares of CeriBell in a research report on Tuesday, October 21st. They issued a "strong-buy" rating and a $19.00 price target on the stock. Finally, JPMorgan Chase & Co. dropped their price objective on shares of CeriBell from $21.00 to $17.00 and set an "overweight" rating on the stock in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $25.17.
Check Out Our Latest Research Report on CBLL
Institutional Trading of CeriBell
Several institutional investors and hedge funds have recently modified their holdings of the business. Sherbrooke Park Advisers LLC acquired a new position in CeriBell during the third quarter worth about $135,000. Millennium Management LLC boosted its position in CeriBell by 41.8% in the third quarter. Millennium Management LLC now owns 666,448 shares of the company's stock valued at $7,657,000 after buying an additional 196,299 shares in the last quarter. Bank of America Corp DE grew its stake in shares of CeriBell by 87.1% during the third quarter. Bank of America Corp DE now owns 135,783 shares of the company's stock worth $1,560,000 after buying an additional 63,215 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of CeriBell during the third quarter worth $33,000. Finally, Two Sigma Investments LP boosted its holdings in shares of CeriBell by 81.0% during the 3rd quarter. Two Sigma Investments LP now owns 297,963 shares of the company's stock valued at $3,424,000 after acquiring an additional 133,324 shares in the last quarter.
About CeriBell
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
